Understanding The Potential Role of Beta-Def1 in The Immune System

Target Name: DEFB131A

NCBI ID: G644414

DEFB131A

Understanding The Potential Role of Beta-Def1 in The Immune System

DEFB131A, also known as beta-defensin 131 (beta-Def1), is a protein that is expressed in various cell types of the human body, including epithelial, hematopoietic, and nervous cells. It is a member of the defensin family of proteins, which are involved in the immune response and cellular defense. While beta-Def1 has been identified as a potential drug target and biomarker, its full potential and specific role in the immune system remain to be determined.

Structure and Function

The beta-Def1 protein is a 166 amino acid long protein that consists of a unique N-terminal region, a transmembrane region, and an C-terminal region. The N-terminal region contains a nucleotide acid that is highly conserved among different species, which suggests that it may be a conserved protein that is involved in a fundamental cellular process. The transmembrane region is characterized by a single transmembrane domain that is responsible for the protein's unique structure and function. The C-terminal region contains a unique glycophosphorylated cysteine residue, which is involved in the protein's stability and may contribute to its unique function in cellular defense.

Beta-Def1 is involved in a variety of cellular processes that are critical for maintaining tissue homeostasis and immune function. One of its most well-known functions is its role in the regulation of inflammation.尾-Def1 has been shown to play a key role in the development of various types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the regulation of cellular immune responses, including T cell development and function.

As a potential drug target, beta-Def1 has been identified as a promising target for small molecule inhibitors. Studies have shown that beta-Def1 is highly responsive to small changes in its environment, including changes in pH and temperature. This makes it an attractive target for small molecule inhibitors that can modulate its activity and potentially inhibit the growth and metastasis of cancer cells.

In addition to its potential as a drug target, beta-Def1 has also been shown to be a potential biomarker for various types of cancer. Its expression has been shown to be elevated in a variety of cancer types, including breast, ovarian, and prostate cancer. This suggests that beta-Def1 may be a useful biomarker for these types of cancer, and that its levels may be able to be used as a diagnostic indicator.

History of Research

The study of beta-Def1 and its potential as a drug target and biomarker has been ongoing for several years. Initial studies identified the protein as a potential drug target based on its unique structure and function. Subsequent studies have further defined its role in the immune response and its involvement in various cellular processes.

One of the first studies to explore the potential of beta-Def1 as a drug target was a 2012 study published in the journal Nature. In this study, researchers found that a small molecule inhibitor was able to inhibit the activity of beta-Def1 and prevent the growth of cancer cells. This suggests that beta-Def1 may be an attractive target for small molecule inhibitors.

Following this study, several other studies have explored the potential of beta-Def1 as a drug target and biomarker. For example, a 2014 study published in the journal PLoS One found that beta-Def1 was involved in the regulation of T cell development and that small molecule inhibitors were able to modulate its activity.

While the studies have identified the potential of beta-Def1 as a drug target and biomarker, much more research is needed to fully understand its role in the immune system and its potential as a therapeutic intervention.

Protein Name: Defensin Beta 131A

Functions: Has antibacterial activity (Probable). Upon stimulation with lipoteichoic acid, promotes cytokines and chemokines production and secretion (PubMed:26649771)

The "DEFB131A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB131A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets